Explanatory video: Nutrition therapy

A sufficient and varied diet is essential to a healthy life. But what happens when the normal intake of food is no longer possible?
Palonosetron Hydrochloride Injection is the newest addition to the company’s expanding portfolio of IV drugs. It is an antiemetic that can be used for chemotherapy-induced nausea and vomiting.
Remifentanil is the newest addition to the company’s extensive portfolio of anesthesia and analgesia products. Remifentanil is a controlled substance sold only to licensed health care professionals for patient care and is distributed under strict controls in compliance with FDA and DEA regulations.
Bortezomib for intravenous use is the first and only available alternative to Bortezomib for Injection and is the newest addition to the company’s expanding oncology portfolio.
Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.
Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.
Fresenius Kabi opened the extension of its production plant in Mihla, Germany, today with a festive dedication ceremony attended by Mayor Rainer Laemmerhirt. The healthcare company invested about €10 million in the project.
In the new production hall, employees will make core injection-molded components for pharmaceutical containers, port systems – which enable infusions to be administered as gently as possible, for example during chemotherapy – and medical disposables. The latter include such products as feeding tubes and giving sets, which are routinely used in hospitals to administer infusion therapies, clinical nutrition and intravenous drugs. The extension will enable Fresenius Kabi to produce components it previously had to purchase from suppliers.
At approximately 1,000 square meters (10,700 square feet), the new hall doubles the amount of space available for production activities at the plant in Mihla, a town in the eastern German state of Thuringia. The project also includes an expansion of the plant’s warehouse to hold as many as 2,000 pallets – a more than six-fold increase.
Dr. Christian Hauer, President Medical Devices Division of Fresenius Kabi, said: “Products from Fresenius Kabi are used in the care of chronically and critically ill patients, which makes the highest standards of quality and reliability essential. Our employees in Mihla have been doing outstanding work for many years. I’m delighted that with this extension, we are making our Mihla production location ready for the future.”
Mayor Laemmerhirt praised Fresenius Kabi for its commitment to his community: “I am very happy that Fresenius Kabi, as a globally active company, is investing here in Mihla. This can also be seen as a positive sign for our region and its economic development.”
Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.
Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.
A sufficient and varied diet is essential to a healthy life. But what happens when the normal intake of food is no longer possible?
Caspofungin, an antifungal medicine, expands the company's sterile injectable anti-infective portfolio.